Mednext Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 15-11-2024
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.59 Cr
as on 15-11-2024
- Satisfied Charges ₹ 10.01 Cr
as on 15-11-2024
- Revenue 60.61%
(FY 2023)
- Profit 116.78%
(FY 2023)
- Ebitda 78.24%
(FY 2023)
- Net Worth 77.84%
(FY 2023)
- Total Assets 37.45%
(FY 2023)
About Mednext Biotech
The Corporate was formerly known as Mednext Biotech Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹16.59 Cr. The company has closed loans amounting to ₹10.01 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anil Vyas, Neelam Vyas, Sunil Chittora, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232RJ2012PLC039813
- Company No.
039813
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
17 Aug 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Udaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Mednext Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Vyas  | Director | 10-Oct-2017 | Current |
| Neelam Vyas | Director | 17-Aug-2012 | Current |
| Sunil Chittora | Director | 03-Feb-2018 | Current |
| Pankaj Vyas | Director | Current |
Financial Performance of Mednext Biotech.
Mednext Biotech Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 60.61% increase. The company also saw a substantial improvement in profitability, with a 116.78% increase in profit. The company's net worth Soared by an impressive increase of 77.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mednext Biotech?
In 2023, Mednext Biotech had a promoter holding of 99.21% and a public holding of 0.79%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Tirtham Hospitality Private LimitedActive 3 years 3 months
Anil Vyas and Neelam Vyas are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 Mar 2022 | ₹15.99 Cr | Open |
Others Creation Date: 16 Mar 2022 | ₹6.00 M | Open |
Others Creation Date: 20 Jul 2020 | ₹6.50 M | Satisfied |
How Many Employees Work at Mednext Biotech?
Mednext Biotech has a workforce of 33 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mednext Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mednext Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
